Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Dechra Pharmaceuticals shares dip back as it says trading in line with expectations

In a trading update for the year ended 30 June 2018, the FTSE 250-listed firm said group revenue for the period increased approximately by 14% at constant exchange rates
Vet with a cat
Dechra said European Pharmaceuticals revenue growth was 11%, while North America Pharmaceuticals revenue growth was 18%

Dechra Pharmaceuticals PLC (LON:DPH) shares had lost earlier gains by late morning on Tuesday as the veterinary drug firm revealed that strong full-year trading was in line with management expectations.

In a trading update for the year ended 30 June 2018, the FTSE 250-listed firm said group revenue for the period increased by approximately 14% at constant exchange rate (CER).

READ: Jefferies gives booster to Dechra Pharma with upgrade to ‘buy’ from ‘hold’ following recent acquisitions

The company said European Pharmaceuticals revenue growth was 11%, while North America Pharmaceuticals revenue growth was 18% at CER.

Dechra also said the integration of AST Farma, Le Vet and RxVet Limited, now Dechra Veterinary Products New Zealand Limited, is proceeding well and trading is in line with expectations.

Ian Page, Dechra's chief executive officer, said: “We are pleased to have delivered another year of strong revenue growth. This has been driven from our core portfolio, good market penetration and recent pipeline launches.”

After opening higher, however, Dechra Pharma's shares had gone into reverse approaching midday, down 1.2% to 2,914p.

In a note to clients, analysts at Numis Securities pointed out: “Dechra’s shares have performed strongly up over 70% over the past 12m as the business delivers on both organic (pipeline/geographic expansion) and M&A and trades at 22x 2019E EV/EBITDA for low-teens EBITDA growth, which we view as well-supported.”

They repeated an ‘add’ rating and 2,950p a share target price on the stock.

 -- Updates share price, adds analyst comment --

View full DPH profile View Profile

Dechra Pharmaceutical Timeline

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use